MedTrace Logo

Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy

NCT06625047 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-29

No results posted yet for this study

Summary

This phase IV trial compares patient satisfaction with telehealth versus in-person neuro-oncology assessments among glioma patients receiving oral chemotherapy. Gliomas are the most common primary central nervous system cancer and are associated with a high symptom burden, such as drowsiness, fatigue, memory difficulty, and difficulty communicating. Care at a high volume center is associated with an overall survival benefit, however, many patients may have physical or financial difficulties preventing access to these centers. Telehealth visits use computers, cameras, videoconferencing, the internet, satellite, and wireless communications to deliver healthcare, while in-person visits require the interaction to take place in the physical presence of someone else. Telehealth neuro-oncology assessments may be preferable compared to in-person assessments in glioma patients receiving oral chemotherapy.

Conditions

  • Astrocytoma, IDH-Mutant
  • Glioblastoma
  • Glioma
  • Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted

Interventions

BEHAVIORAL

Assessment

Complete in-person assessment visits

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Telemedicine Visit

Complete telehealth assessment visits

DRUG

Temozolomide

Given PO

Sponsors & Collaborators

Principal Investigators

  • Ugur T. Sener, MD · Mayo Clinic

  • Tufia C. Haddad, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-07
Primary Completion
2025-11-12
Completion
2025-11-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06625047 on ClinicalTrials.gov